Avania Buys Spanish Medtech CRO Anagram

Avania has expanded its European footprint with the purchase of Spanish medtech contract research organization (CRO) Anagram. Neither company disclosed the selling price.

Founded in 1998, Anagram delivers a full service CRO model to customers, including diagnostic imaging core lab (centralized quality control and central assessment of images in clinical trials services. It is focused on cardiology, oncology, and neurology therapeutic areas. The firm conducts studies in the United States, United Kingdom, Spain, Netherlands, France, and Germany, among other countries.

Anagram is a good fit for Avania, enabling the company to increase CRO business in Spain and providing greater access to a growing medtech region, according to Avania. The addition will support cross-sell opportunities by adding scale and will eliminate reliance on current outsourcing partners. Avania customers will benefit from an expanded geographic footprint and an enhanced roster of subject matter experts concentrated on areas of key therapeutic expertise, Avania executives claim.

“The addition of Anagram furthers our vision of becoming a trusted global partner for the medtech community, advancing innovations from bench to bedside and improving patient outcomes globally,” Avania President/CEO Jason Monteleone said. “It will provide us with a significant footprint in Spain and Southern Europe and further strengthen our cardiovascular and neurology franchises while expanding our oncology capabilities.”

Avania is a global medtech clinical research organization and advisory partner with a focus on medical devices, diagnostics/IVDs, and digital health. Core offerings include full service clinical research outsourcing, market access, reimbursement, regulatory, and product development advisory services. Avania’s vision is to be a trusted global partner in the evolution of medical technology from innovation and commercialization to improving patient health and well-being.

Anagram is a Spanish CRO that provides high quality services in clinical development and post-authorization trials for drugs and medical devices. Services include image central reading (core lab), analysis, and reporting by highly experienced professionals. Anagram has specialized expertise in cardiology, neurology, and oncology.